Acuity RM shares soar as cost-cutting results in profitable trading

Acuity RM reported FY2025 revenue of about £2.1m (unchanged from 2024, unaudited) while administrative costs fell c.27% to £2.2m from £3.0m, with annualised overheads down to £1.8m by Q4 and the group trading profitably in Oct–Dec. Forward contracted revenue slipped to £1.9m (from £2.5m a year earlier) and the NextGen STREAM release was delayed to Q1 2026; the cost cuts and profitable quarter-end drove a c.36% jump in the AIM-listed share price to 0.96p. Investors should weigh improved near-term cash burn and profitability against weaker forward bookings and the product launch delay.

Analysis

Market structure: The immediate winners are Acuity RM (AIM:ACRM) shareholders and momentum traders; losers are short-term creditors and any vendors expecting quick growth. Cost cuts (admin -27% to ~£2.2m; Q4 annualised overheads £1.8m) materially extend runway — profitable trading in Oct–Dec shows operating leverage — but forward contracted revenue fell 24% y/y to £1.9m, signalling weaker demand to date. Cross-asset impact is negligible beyond higher implied vol in AIM small-cap tech names and potential widening of credit spreads for similar microcaps due to idiosyncratic risk repricing.

Risk assessment: Tail risks include NextGen STREAM failing on launch or missing sales targets (Q1 2026 catalyst), an adverse audit adjusting management accounts, or an unexpected cash raise leading to >10–30% dilution. Timeline: immediate (days) = momentum/mean reversion risk after +36% move to 0.96p; short-term (weeks) = product release and initial contract flow; long-term (quarters) = renewal/recurring revenue growth and ability to sustain reduced overheads. Hidden dependencies: revenue concentration, recognition timing, and liquidity (penny-stock volatility) can amplify moves.

Trade implications: Tactical, small-size long exposure to ACRM up to 1–2% portfolio if bought at ≤0.95p with hard stop 0.6p and a take-profit or re-eval at 2.0p; scale to 3–5% only if NextGen ships in Q1 and new contracted bookings ≥£0.5m within 90 days. If options/liquidity exist, use a 3-month call spread (buy 0.8p / sell 2.0p) to cap cost; alternatively hedge with a short position in a broad AIM tech basket or relative short in LON:KNOS to isolate idiosyncratic upside. Sector tweak: rotate small weight from overvalued, revenue-rich software names into profitable microcaps showing positive monthly EBIT.

Contrarian angles: The 36% rally likely overprices management execution — forward contracted revenue decline (£2.5m→£1.9m) is not priced in. Historical parallels show penny software stocks spike on cost cuts then fall when product rollout fails to convert; if NextGen misses Q1 2026 or contracted revenue at next report <£1.8m, expect >40% downside from current levels. Position sizing should be capped and event-driven.

Key Decisions for Investors

• Establish a tactical long in AIM:ACRM sized 1–2% of portfolio if entry price ≤0.95p; set a stop-loss at 0.6p and pre-set take-profit / reassessment at 2.0p or upon Q1 2026 update.
• If NextGen STREAM is released in Q1 2026 and Acuity reports ≥£0.5m of new forward contracted bookings within 90 days, scale the position to 3–5% of portfolio and target a re-rating to >£2.5m forward revenue within 6 months.
• Hedge idiosyncratic risk by shorting an AIM tech basket (or take a modest short in LON:KNOS equal notional) to isolate Acuity-specific upside; reduce hedge if sector beta falls below 0.7 over 30 days.
• If liquid options exist, implement a 3-month call spread on ACRM (buy 0.8p / sell 2.0p) sized to cap max premium to ≤0.5% of portfolio; if options unavailable, use the stock + hedge approach above.
• Cut or exit position immediately if (a) NextGen misses the announced Q1 2026 window, (b) next trading update shows forward contracted revenue <£1.8m, or (c) management announces a cash raise implying >20% dilution.